This study was completed in collaboration between Kent State University and Akron Children's Hospital and served as a doctoral dissertation (NRN), supported by a grant from the Ohio Board of Regents (DLD). Manuscript preparation was supported, in part, by NIMH grants T32 078788 (NRN), K01 MH087240 (NRN), R34 MH71201 (DLD), and R34 MH 73014 (DLD).
The efficacy of early propranolol administration at reducing PTSD symptoms in pediatric injury patients: A pilot study†
Version of Record online: 6 APR 2010
Copyright © 2010 International Society for Traumatic Stress Studies
Journal of Traumatic Stress
Volume 23, Issue 2, pages 282–287, April 2010
How to Cite
Nugent, N. R., Christopher, N. C., Crow, J. P., Browne, L., Ostrowski, S. and Delahanty, D. L. (2010), The efficacy of early propranolol administration at reducing PTSD symptoms in pediatric injury patients: A pilot study. J. Traum. Stress, 23: 282–287. doi: 10.1002/jts.20517
- Issue online: 19 APR 2010
- Version of Record online: 6 APR 2010
Initial research supports the use of propranolol to prevent posttraumatic stress disorder (PTSD); research has not examined pharmacological prevention for children. Twenty-nine injury patients (ages 10–18 years old) at risk for PTSD were randomized to a double-blind 10-day trial of propranolol or placebo initiated within 12 hours postadmission. Six-week PTSD symptoms and heart rate were assessed. Although intent-to-treat analyses revealed no group differences, findings supported a significant interaction between gender and treatment in medication-adherent participants, ΔR2 = .21. Whereas girls receiving propranolol reported more PTSD symptoms relative to girls receiving placebo, ΔR2 = .44, boys receiving propranolol showed a nonsignificant trend toward fewer PTSD symptoms than boys receiving placebo, ΔR2 = .32. Findings inform gender differences regarding pharmacological PTSD prevention in youth.